Stay updated with breaking news from Stericon Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Private equity firm InvAscent plans to list five portfolio companies in the health and pharmaceutical sectors over the next 24–36 months, providing exit opportunities for the investor.
Nirma's tryst with the pharmaceutical space started in 2006 when it acquired the ailing Core Healthcare in a deal reported to be worth Rs 300 crore. The Ahmedabad-based manufacturer of intravenous fluids was subsequently renamed Nirlife. Pharma industry insiders say Nirma, which broke open the detergent market in the 1990s with low prices and massive advertising, tried an encore of the low-price strategy in pharma, but with mixed results.
India Business News: Ahmedabad-based Nirma is set to acquire Glenmark Life Sciences (GLS), a subsidiary of Glenmark Pharma, for Rs 5,652 crore. This move marks Nirma's ent
Glenmark Pharmaceuticals has entered into a share purchase agreement with Nirma Limited to divest a 75% stake in Glenmark Lifesciences at a price of Rs 615 per share.
Glenmark Pharmas stake in the leading active pharmaceutical ingredient (API) platform will drop to 7.84% from 82.84%. The transaction values the company at Rs 7,535.4 crore, a slight discount to the current market value of Rs 7,683 crore. The acquisition will trigger a mandatory open offer to all public shareholders of GLS for an additional 17%.